A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

Nakayama Clinic, Nagoya

Shinkashiwa Clinic, Kashiwa

Kashiwa City Hospital, Kashiwa

Tokuyama Clinic, Mihama-ku,Chiba City

Mikannohana Clinic, Diabetes, Endocrinology and Metabolism, Matsuyama

Steel Memorial Yawata Hospital, Kitakyushu

Hasegawa Medical Clinic, Chitose

Odori Diabetes, Sapporo

Matsuda Clinic, Kobe

Nakamoto Internal Medicine Clinic, Mito

MinamiAkatsukaClinic, Mito

Nakakinen clinic, Naka

Nishiyamadou Keiwa Hospital, Naka

Taya Clinic Koueikai Medical Corporation, Tsuchiura

Shonan Takai Clinic, Kamakura

Takai Internal Medicine Clinic, Kamakura-shi

Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi

Yokohama Minoru Clinic, Yokohama

Yokkaichi Diabetes Clinic, Yokkaichi

Gibo Hepatology Clinic, Matsumoto

Shiraiwa Medical Clinic, Kashihara

Kitada Clinic, Osaka

Medical Corporation Heishinkai OCROM Clinic, Suita-shi

OHAMA Diabetes Clinic, Kawaguchi

Sugiura Internal Medicine Clinic, Sōka

Seiwa Clinic, Adachi-ku

The Institute for Adult Disease, Asahi Life Foundation, Chuo-ku

Tokyo-Eki Center-building Clinic, Chuo-ku

Fukuwa Clinic, Chuo-ku

Hachioji Diabetes Clinic, Hachioji-shi

Kanno Naika, Mitaka

Heishinkai Medical Group ToCROM Clinic, Shinjuku-ku

Medical Corporation Tao Internal Medicine Clinic, Ube

Fujii Clinic, Ube

Tashiro Endocrinology Clinic, Fukuoka

Morinaga Ueno Clinic, Kumamoto

Jinnouchi Hospital, Kumamoto

Heiwadai Hospital, Miyazaki

Kansai Electric Power Hospital, Osaka

Abe Clinic, Ōita